Selective Targeting of Procoagulant Platelets

A process for identifying a patient at risk of developing a prothrombotic or thrombotic condition, comprising contacting a platelet from said patient with a compound and determining whether the compound binds to the platelet, wherein the compound is an arsenoxide (or arsenoxide equivalent) compound.

A process for identifying a compound which inhibits formation of procoagulant platelets, wherein said process comprises contacting a sample comprising platelets with a compound and determining whether the compound inhibits formation of procoagulant platelets.

A process for screening a plurality of compounds to identify a compound which selectively inhibits formation of procoagulant platelets, wherein said process comprises contacting a sample comprising platelets with the plurality of compounds, determining whether any of the compounds inhibit formation of procoagulant platelets, and if so, separately determining for each of the plurality of compounds whether the compound inhibits formation of procoagulant platelets.